Biotechs often need several years to realize their visions, even after they have a drug approved for the first time. There's typically plenty of upside in store for enterprising and patient investors.
USA News Group News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – USA News Group News Commentary – As many biotech companies within the oncology space begin to roll...
/CNW/ -- USA News Group News Commentary – As many biotech companies within the oncology space begin to roll out their end-of-quarter results, the American...
Iovance Biotherapeutics: Q3 Earnings Snapshot
With a cutting-edge melanoma drug now on the market, the company is positioned for a breakout.
The biotech is making important breakthroughs, but is that enough?
This biotech's growth story is going to start moving faster, and soon.
There's plenty of upside with this stock, but it might take a while to realize.